Screener / SEC EDGAR /CIK 0001088856 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Corcept Therapeutics Inc CORT

We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. 10-K, Item 1

Headquarters
Redwood City, CA
CEO
Joseph K. Belanoff
Next results
around Feb 23, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $761.4M through the costs to a net profit of $99.7M · income statement of the 10-K

6% operating margin
Revenue to Gross profit: $748.4MRevenue to Cost of revenue: $13.0MGross profit to Operating profit: $44.8MGross profit to Operating expenses: $703.6MOperating profit to Net profit: $44.8MOther income to Net profit: $54.9MOperating expenses to R&D: $254.9MOperating expenses to SG&A: $448.7M Revenue: $761.4M REVENUE $761.4M +13% Y/Y Gross profit: $748.4M · 98% margin GROSS PROFIT $748.4M 98% margin Cost of revenue: $13.0M · 2% of revenue COST OF REVENUE $13.0M 2% of revenue Operating profit: $44.8M · 6% margin OPERATING PROFIT $44.8M 6% margin · −67% Y/Y Other income: $54.9M · 7% of revenue OTHER INCOME $54.9M 7% of revenue Operating expenses: $703.6M · 92% of revenue OPERATING EXPENSES $703.6M 92% of revenue Net profit: $99.7M · 13% margin NET PROFIT $99.7M 13% margin · −29% Y/Y R&D: $254.9M · 33% of revenue R&D $254.9M 33% of revenue SG&A: $448.7M · 59% of revenue SG&A $448.7M 59% of revenue
Gross profit $748.4M 98% margin
Operating profit $44.8M 6% margin · −67% Y/Y
Net profit $99.7M 13% margin · −29% Y/Y
The full income statement, year by year

CORT among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 12.8%, above 59% of 154 peers (their median 10.4%) REVENUE GROWTH 12.8% · above 59% Operating margin: 11.5%, above 57% of 138 peers (their median 9.8%) OPERATING MARGIN 11.5% · above 57% Net margin: 16.8%, above 78% of 153 peers (their median 6.7%) NET MARGIN 16.8% · above 78% FCF margin: 20.2%, above 78% of 144 peers (their median 9.9%) FCF MARGIN 20.2% · above 78% Return on capital: 8.1%, above 38% of 89 peers (their median 9.2%) RETURN ON CAPITAL 8.1% · above 38%
CORT Peer median Below the median

What changed

29 new risk paragraphs. 10-K filed Feb 24, 2026 against Feb 26, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +10.8% ($54.0M to $59.8M) vs revenue +12.8% ($675.0M to $761.4M), -2.0 pts apart
  • Cash from operations $142.0M vs net income $99.7M (FY ending Dec 31, 2025)
  • Inventory +3.7% ($12.4M to $12.9M) vs revenue +12.8% ($675.0M to $761.4M), -9.1 pts apart
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Net Product Revenue - Accounting for Government Rebates
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

29 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.

All 29 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at the HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    We do not currently have nor do we have immediate plans to acquire the infrastructure or internal capability to manufacture our clinical drug supplies for use in the conduct of our clinical trials, and we lack the internal resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. The…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    We cannot sell a product without the approval of the FDA, EMA or comparable regulatory authority. Obtaining such approval is difficult, uncertain, lengthy and expensive. Failure can occur at any stage. In order to receive FDA approval for a new drug, we must demonstrate to the FDA’s satisfaction that the new drug is safe and effective…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    We submitted an NDA for relacorilant as a treatment for patients with hypercortisolism. On December 30, 2025, the FDA issued a CRL declining to approve relacorilant for the proposed use and stating that additional evidence of effectiveness was required. We plan to meet with the FDA to arrive at the best path to approval. We have also…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$401.9M$482.4M$675.0M$761.4M
Net income$101.4M$106.1M$141.2M$99.7M
Operating cash flow$120.3M$126.7M$198.3M$142.0M
Free cash flow$119.9M$126.5M$196.1M$141.8M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$761.4M ▲ 12.8% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

7 filings in the last 30 days · SEC EDGAR

All filings
2 more

About the company

Corcept Therapeutics Inc, Redwood City, CA · from the 10-K filed Feb 24, 2026

We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. Cortisol plays a significant role in the body’s response to stress and is essential for survival. Cortisol influences metabolism and the immune system and contributes to emotional stability. Cortisol levels follow a diurnal rhythm that is essential to health, peaking upon awakening and decreasing during the day. Insufficient cortisol activity may lead to dehydration, hypotension, shock, fatigue and hypoglycemia.

Headquarters
Redwood City, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 3, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CORT/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.